Show simple item record

dc.contributor.authorFong, C. Y. K.
dc.contributor.authorIyer, S.
dc.contributor.authorPotts, L.
dc.contributor.authorPeckitt, C.
dc.contributor.authorCromarty, S.
dc.contributor.authorSaffery, C.
dc.contributor.authorKidd, S.
dc.contributor.authorRana, T.
dc.contributor.authorAusec, L.
dc.contributor.authorGregorc, A.
dc.contributor.authorPointing, D.
dc.contributor.authorGombert, M.
dc.contributor.authorVon Loga, K.
dc.contributor.authorBenjamin, L.
dc.contributor.authorStarling, N.
dc.contributor.authorWaddell, Thomas
dc.contributor.authorPetty, R.
dc.contributor.authorUhlik, M.
dc.contributor.authorChau, I.
dc.contributor.authorCunningham, D.
dc.date.accessioned2023-01-24T10:32:24Z
dc.date.available2023-01-24T10:32:24Z
dc.date.issued2022en
dc.identifier.citationFong CYK, Iyer S, Potts L, Peckitt C, Cromarty S, Saffery C, et al. Predicting benefit from maintenance durvalumab after firstline chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assay. Annals of Oncology. 2022 Sep;33(7):S1110-S. PubMed PMID: WOS:000866211601487.en
dc.identifier.doi10.1016/j.annonc.2022.07.1344en
dc.identifier.urihttp://hdl.handle.net/10541/625968
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.07.1344en
dc.titlePredicting benefit from maintenance durvalumab after firstline chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA-based assayen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGastrointestinal/Lymphoma Unit, The Royal Marsden NHS Foundation Trust, London and Sutton, UK;en
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record